A pilot feasibility study of a behavioral intervention for nicotine vaping cessation among young adults delivered via telehealth.

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

Many youth who vape indicate interest in quitting; however, few empirically supported vaping cessation interventions exist.

This pilot feasibility study adapted an established behavioral intervention, contingency management (CM), delivered via telehealth to promote vaping cessation among young adults.

Who Took Part

The age groups tagged for this paper are teenagers, young adults and adults.

Participants (N = 27; ages 17-21) vaping nicotine regularly were recruited via social media and digital advertisements from across the US (June 2020-January 2021).

Participants were randomized at approximately 4:1 to CM or Monitoring control (22:5).

How the Study Was Run

In design terms this was a randomized and pilot study.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

It is described as a pilot, a small early test of whether a larger Therapeutic nicotine (patch, non-peptide) study would be practical.

Control participants earned incentives for submitting cotinine, regardless of abstinence.

Feasibility, acceptability, and abstinence was collected throughout treatment, at EOT, and at 1-month follow-up.

What Was Measured

PubMed files the paper under topics including Electronic Nicotine Delivery Systems, Feasibility Studies, Pilot Projects, Smoking Cessation, Telemedicine and Vaping.

Author keywords: Contingency management, Electronic cigarettes, Telehealth, Treatment and Youth.

What This Means in Plain Language

The paper is a randomized and pilot study of Therapeutic nicotine (patch, non-peptide).

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2022 (Drug and alcohol dependence), a journal based in Ireland.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.